Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity

Core Insights - Biogen Inc. announced positive results from the Phase 2 part of the AMETHYST study for litifilimab, a monoclonal antibody targeting cutaneous lupus erythematosus (CLE), potentially marking the first new therapy for CLE in 70 years [1][5][12] Study Results - The AMETHYST Phase 2 study demonstrated a statistically significant 11.8% higher reduction in disease activity at Week 16 for litifilimab compared to placebo, with a reduction of 14.7% versus 2.9% [4][6] - Secondary endpoints showed rapid improvement in skin disease activity, with separation from placebo observed as early as Week 4, and a CLASI-50 response of 40.8% for litifilimab versus 21% for placebo at Week 24 [4][5] - The study enrolled a diverse population, with 74% of participants being women and 33% non-white, reflecting the epidemiology of CLE [3][4] Safety Profile - Litifilimab was generally well tolerated, with adverse events reported in 74.6% of participants receiving litifilimab and 64.7% in the placebo group, mostly mild to moderate in severity [7][8] - Serious adverse events occurred in 6.8% of litifilimab participants compared to 2.9% in the placebo group [7] Market Context - Currently, there are no approved targeted therapies for CLE, with the last drug approved in the 1950s, highlighting a significant unmet need in the market [12][8] - The positive results from the AMETHYST study, alongside the FDA Breakthrough Therapy Designation, position litifilimab as a potential first-in-class treatment for CLE [2][5]